# China NMPA Drug Inspection - Beijing Yanjing Pharmaceutical Co., Ltd. - Atorvastatin calcium tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/beijing-yanjing-pharmaceutical-co-ltd/419ae336-f0d1-4f27-bc98-fa1ee36b7c4e/
Source feed: China

> China NMPA drug inspection for Beijing Yanjing Pharmaceutical Co., Ltd. published October 11, 2018. Drug: Atorvastatin calcium tablets. The Heilongjiang Provincial Food and Drug Administration issued an announcement on October 11, 2018, to rectify informat

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Provincial Bureau Regarding Corrections to Drug Supervision and Sampling Information
- Company Name: Beijing Yanjing Pharmaceutical Co., Ltd.
- Publication Date: 2018-10-11
- Drug Name: Atorvastatin calcium tablets
- Inspection Finding: The drug identification (ultraviolet spectroscopy) test was unsatisfactory; it was verified that the drug was not manufactured by the company indicated on the label (batch number 161229).
- Action Taken: This corrects the previously released information regarding random inspections, clarifying that this batch of drugs was not produced by Beijing Jialin Pharmaceutical Co., Ltd.
- Summary: The Heilongjiang Provincial Food and Drug Administration issued an announcement on October 11, 2018, to rectify information concerning drug supervision and sampling. This correction followed an earlier report (2018, No. 8) which identified two batches (161223 and 161229) of Atorvastatin Calcium Tablets as unqualified. These batches were initially attributed to Beijing Jialin Pharmaceutical Co., Ltd. However, subsequent investigation, initiated by an application from the named company and confirmed by the drug regulatory department, established that Beijing Jialin Pharmaceutical Co., Ltd. was not the actual producer of these substandard drugs. The products had failed critical identification tests using Ultraviolet Spectroscopy, indicating a significant quality violation. Operating within the regulatory framework of China's drug administration, the provincial authority's immediate required action was to publicly correct this inaccurate attribution, ensuring transparency and factual accuracy in drug sourcing and oversight. This correction implicitly underscores the need for further regulatory efforts to identify the true manufacturer of these non-compliant pharmaceuticals and address the root cause of the quality issues.

Company: https://www.globalkeysolutions.net/companies/beijing-yanjing-pharmaceutical-co-ltd/560f870c-c041-4d9f-bbbc-fb56f1a026f5/